439 related articles for article (PubMed ID: 30973486)
21. Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.
Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA
Exp Hematol; 2015 Dec; 43(12):1001-1014.e5. PubMed ID: 26384559
[TBL] [Abstract][Full Text] [Related]
22. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report.
Wen S; Niu Z; Xing L; Wang Y; Li H; Kuang N; Luo J; Zhang X; Wang F
BMC Cancer; 2018 Nov; 18(1):1143. PubMed ID: 30458755
[TBL] [Abstract][Full Text] [Related]
23. Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor.
Zhang R; Deng Q; Jiang YY; Zhu HB; Wang J; Zhao MF
Oncol Rep; 2019 Jun; 41(6):3455-3463. PubMed ID: 30942469
[TBL] [Abstract][Full Text] [Related]
24. CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yao Z; Gu B; Zhang Y; Qi J; Chen J; Xu Y; Chen F; Ma X; Miao M; Xue S; Qiu H; Tang X; Han Y; Chen S; Sun A; Yu L; Wu D; Wang Y
Bone Marrow Transplant; 2023 Jan; 58(1):103-105. PubMed ID: 36253466
[No Abstract] [Full Text] [Related]
25. Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.
Holland EM; Yates B; Steinberg SM; Yuan CM; Wang HW; Annesley C; Shalabi H; Stroncek D; Fry TJ; Krueger J; Jacoby E; Hsieh E; Bhojwani D; Gardner RA; Maude SL; Shah NN
Transplant Cell Ther; 2023 Sep; 29(9):574.e1-574.e10. PubMed ID: 37394115
[TBL] [Abstract][Full Text] [Related]
26. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement.
Zoghbi A; Zur Stadt U; Winkler B; Müller I; Escherich G
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28453885
[TBL] [Abstract][Full Text] [Related]
27. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
[TBL] [Abstract][Full Text] [Related]
28. Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy.
Yurkiewicz I; Craig J; Muffly L
Curr Hematol Malig Rep; 2020 Jun; 15(3):187-193. PubMed ID: 32358681
[TBL] [Abstract][Full Text] [Related]
29. Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.
Nagle K; Tafuto B; Palladino Kim L; Parrott JS
Med Oncol; 2018 Sep; 35(11):144. PubMed ID: 30206753
[TBL] [Abstract][Full Text] [Related]
30. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
31. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR
Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811
[TBL] [Abstract][Full Text] [Related]
32. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
Luskin MR; DeAngelo DJ
Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
[TBL] [Abstract][Full Text] [Related]
33. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
Yang X; Dai H; Kang L; Qu C; Li Z; Yin J; Qiu H; Fu C; Han Y; Jin Z; Ma X; Zhu X; Yu L; Wu D; Tang X
Hematol Oncol; 2019 Dec; 37(5):655-658. PubMed ID: 31656047
[No Abstract] [Full Text] [Related]
34. CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.
Fischer J; Paret C; El Malki K; Alt F; Wingerter A; Neu MA; Kron B; Russo A; Lehmann N; Roth L; Fehr EM; Attig S; Hohberger A; Kindler T; Faber J
J Immunother; 2017 Jun; 40(5):187-195. PubMed ID: 28441264
[TBL] [Abstract][Full Text] [Related]
35. INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic Leukemia.
Lamble AJ; Moskop A; Pulsipher MA; Maude SL; Summers C; Annesley C; Baruchel A; Gore L; Amrolia P; Shah N
Transplant Cell Ther; 2023 Nov; 29(11):674-684. PubMed ID: 37689393
[TBL] [Abstract][Full Text] [Related]
36. Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL).
Shouse G; Budde E; Forman S
Cancer Treat Res; 2021; 181():179-196. PubMed ID: 34626362
[TBL] [Abstract][Full Text] [Related]
37. Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in
Fournier E; Inchiappa L; Delattre C; Pignon JM; Danicourt F; Bemba M; Roche-Lestienne C; Daudignon A; Decool G; Roumier C; Dumezy F; Fournier L; Grardel N; Preudhomme C; Duployez N
Leuk Lymphoma; 2019 Jul; 60(7):1827-1830. PubMed ID: 30616415
[No Abstract] [Full Text] [Related]
38. Chimeric Antigen Receptor T-cell Therapy: Current Status and Clinical Outcomes in Pediatric Hematologic Malignancies.
Talleur AC; Myers R; Annesley C; Shalabi H
Hematol Oncol Clin North Am; 2022 Aug; 36(4):701-727. PubMed ID: 35780062
[TBL] [Abstract][Full Text] [Related]
39. Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.
Kenderian SS; Porter DL; Gill S
Biol Blood Marrow Transplant; 2017 Feb; 23(2):235-246. PubMed ID: 27638367
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion.
Ni F; Yin ETS; Zhou L; Zhao H; Luo Y; Shi J; Hu Y; Huang H
Bone Marrow Transplant; 2022 Feb; 57(2):326-328. PubMed ID: 35067672
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
